Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

An in vivo platform for tumor biomarker assessment.

Servais EL, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleisher M, Rusch VW, Sadelain M, Adusumilli PS.

PLoS One. 2011;6(10):e26722. doi: 10.1371/journal.pone.0026722. Epub 2011 Oct 26.

2.

Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.

Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R.

J Thorac Oncol. 2011 Sep;6(9):1587-93. doi: 10.1097/JTO.0b013e31821e1c08.

3.

Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.

Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, Rusch V, Fleisher M.

Clin Chem Lab Med. 2010 Feb;48(2):271-8. doi: 10.1515/CCLM.2010.066.

PMID:
20131968
4.

Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.

Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquée L, De Vuyst P, Germonpré P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP.

J Thorac Oncol. 2011 Nov;6(11):1930-7. doi: 10.1097/JTO.0b013e3182272294.

5.

Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G.

J Clin Oncol. 2010 Jul 10;28(20):3316-22. doi: 10.1200/JCO.2009.26.9944. Epub 2010 May 24.

PMID:
20498407
6.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

7.

Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.

Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2013 Jun;33(6):2707-13.

PMID:
23749930
8.

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.

Pantazopoulos I, Boura P, Xanthos T, Syrigos K.

Eur Respir J. 2013 Mar;41(3):706-15. doi: 10.1183/09031936.00226111. Epub 2012 Jul 26. Review.

9.

Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.

Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2014 Dec;34(12):7425-9.

PMID:
25503183
10.

Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.

Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.

Cancer Invest. 2013 Jan;31(1):43-50. doi: 10.3109/07357907.2012.749265. Epub 2012 Dec 18.

PMID:
23249166
11.

Soluble mesothelin-related protein--a blood test for mesothelioma.

Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I.

Lung Cancer. 2005 Jul;49 Suppl 1:S109-11.

PMID:
15950789
12.

Clinical utility of diagnostic markers for malignant pleural mesothelioma.

Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A.

Monaldi Arch Chest Dis. 2009 Mar;71(1):31-8. Review. Erratum in: Monaldi Arch Chest Dis. 2009 Jun;71(2):88.

PMID:
19522163
13.

Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K.

Lung Cancer. 2008 Aug;61(2):235-43. doi: 10.1016/j.lungcan.2007.12.025. Epub 2008 Feb 20.

PMID:
18281122
14.

Biomarkers for mesothelioma.

Scherpereel A, Lee YC.

Curr Opin Pulm Med. 2007 Jul;13(4):339-443. Review.

PMID:
17534183
15.

Serum and pleural fluid biomarkers for mesothelioma.

Creaney J, Robinson BW.

Curr Opin Pulm Med. 2009 Jul;15(4):366-70. doi: 10.1097/MCP.0b013e32832b98eb. Review.

PMID:
19417672
16.

Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide.

Dipalma N, Luisi V, Di Serio F, Fontana A, Maggiolini P, Licchelli B, Mera E, Bisceglia L, Galise I, Loizzi M, Pizzigallo MA, Molinini R, Vimercati L.

Int J Biol Markers. 2011 Jul-Sep;26(3):160-5. doi: 10.5301/JBM.2011.8614. Epub 2011 Sep 5.

PMID:
21928246
17.

Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.

Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M.

Dis Markers. 2012;32(2):123-31. doi: 10.3233/DMA-2011-0866.

18.

The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.

Nelson HH, Almquist LM, LaRocca JL, Plaza SL, Lambert-Messerlian GM, Sugarbaker DJ, Bueno R, Godleski JJ, Marsit CJ, Christensen BC, Kelsey KT.

Epigenetics. 2011 Aug;6(8):1029-34. doi: 10.4161/epi.6.8.16074. Epub 2011 Aug 1.

19.

Asbestos-related disease: screening and diagnosis.

Rodríguez Portal JA.

Adv Clin Chem. 2012;57:163-85. Review.

PMID:
22870590
20.

Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.

Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P.

Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60. Epub 2006 Feb 2.

PMID:
16456138

Supplemental Content

Support Center